Fenticonazole is an imidazole antifungal drug, used locally as the nitrate in the treatment of vulvovaginal candidiasis. It is active against a range of organisms including dermatophyte pathogens, Malassezia furfur, and Candida albicans. Fenticonazole has also been shown to exhibit antibacterial action, with a spectrum of activity that includes bacteria commonly associated with superinfected fungal skin and vaginal infections, and antiparasitic action against the protozoan Trichomonas vaginalis.
|
Read full article at Wikipedia
|
InChI=1S/C24H20Cl2N2OS.HNO3/c25-19-8-11-22(23(26)14-19)24(15-28-13-12-27-17-28)29-16-18-6-9-21(10-7-18)30-20-4-2-1-3-5-20;2-1(3)4/h1-14,17,24H,15-16H2;(H,2,3,4) |
FJNRUWDGCVDXLU-UHFFFAOYSA-N |
O[N+]([O-])=O.Clc1ccc(C(Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1 |
|
antibacterial drug
A drug used to treat or prevent bacterial infections.
antifungal drug
Any antifungal agent used to prevent or treat fungal infections in humans or animals.
(via imidazole antifungal drug )
(via conazole antifungal drug )
antifungal agent
An antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
(via imidazole antifungal agent )
(via conazole antifungal agent )
ergosterol biosynthesis inhibitor
Any compound that inhibits one or more steps in the pathway leading to the synthesis of ergosterol.
(via conazole antifungal agent )
|
|
antibacterial drug
A drug used to treat or prevent bacterial infections.
antifungal drug
Any antifungal agent used to prevent or treat fungal infections in humans or animals.
(via imidazole antifungal drug )
(via conazole antifungal drug )
|
|
View more via ChEBI Ontology
rac-1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]-1H-imidazole nitrate
|
(+-)-1-(2,4-Dichloro-beta-((p-(phenylthio)benzyl)oxy)phenethyl)imidazole mononitrate
|
ChemIDplus
|
alpha-(2,4-Dichlorophenyl)-beta,N-imidazolylethyl-4-phenylthiobenzyl ether nitrate
|
ChemIDplus
|
fenticonazole mononitrate
|
ChEBI
|
6564060
|
Reaxys Registry Number
|
Reaxys
|
73151-29-8
|
CAS Registry Number
|
ChemIDplus
|
73151-29-8
|
CAS Registry Number
|
KEGG DRUG
|
Fernández-Alba J, Valle-Gay A, Dibildox M, Vargas JA, González J, García M, López LH, Fentimex Mexican Study Group (2004) Fenticonazole nitrate for treatment of vulvovaginitis: efficacy, safety, and tolerability of 1-gram ovules, administered as ultra-short 2-day regimen. Journal of chemotherapy (Florence, Italy) 16, 179-186 [PubMed:15216954] [show Abstract] Because of its potential as a low cost first-line monotherapy for the most common vulvovaginal infections, we evaluated fenticonazole nitrate in a prospective, open-label, multicenter pilot study with 101 sexually active women (per-protocol; 16 to 61 years of age) with vulvovaginitis involving single or mixed infections with Candida albicans, Trichomonas vaginalis, and/or Gardnerella vaginalis. Fenticonazole nitrate (1 g) was administered as vaginal ovules, once daily on days 1 and 3. Eradication (direct phase-contrast microscopy of vaginal swabs and/or microbiological culture) on day 8 was 90% (C. albicans, 26/29, p < 0.001), 70% (T. vaginalis, 7/10, p = 0.161), 67% (G. vaginalis, 22/33, p < 0.009), and 45% (mixed infection, 13/29, p = 0.001). After 28 days, relapse was 0% for candidiasis and trichomoniasis, 27% (6/22) for G. vaginalis, and 23% (3/13) for mixed infection. Overall, eradication of all offending pathogens was achieved in 67% of the total per-protocol population, with a relapse rate of only 16%. Score sums for symptoms improved from 7.0 (baseline) to 1.7 (day 8), and 0.71 (day 28), (p < 0.001). Treatment was safe and well tolerated. The results of our pilot study suggest that application of fenticonazole nitrate 1 g intravaginal ovules on 2 alternate days is a suitable first-line treatment of vulvovaginitis with acceptable broad-spectrum efficacy against the most commonly involved pathogens and with a low rate of early relapse, reserving antibiotics for patients with treatment failure or relapse of infection. Our results should encourage further examination of this approach in larger and well controlled clinical trials. | Muñoz Reyes JR, Villanueva Reynoso C, Ramos CJ, Menéndez Vázquez J, Bailón Uriza R, Vargas AJ (2002) [Efficacy and tolerance of 200 mg of fenticonazole versus 400 mg of miconazole in the intravaginal treatment of mycotic vulvovaginitis]. Ginecologia y obstetricia de Mexico 70, 59-65 [PubMed:12017948] [show Abstract]
ObjectiveFenticonazole is an imidazole derivative with a broad-spectrum antifungal activity mainly against Candida albicans. Fenticonazole nitrate was compared to myconazole vs. test efficacy, tolerance and treatment compliance in-patients with mycotic vulvovaginitis.Patients and methodEighty outpatients with mycotic vulvovaginitis were included and randomly placed in two groups of forty patients each one. Each group was either given 200 mg of fenticonazole nitrate intravaginal ovules or 400 mg of myconazole vaginal ovules on a daily basis for three days. Before the pharmacological treatment, each patient was evaluated clinically and microbiologically, as well as at the end of treatment (day 7-10) and one-month (28 days) after treatment. All patients gave informed consent to participate in the trial.ResultsNo statistical differences were found between either treatment group during the anthropometric and demographic evaluation, neither in the signs and clinical symptoms of infection. Both treatment groups were considered as comparable. At after treatment evaluation (7-10 days) it was observed disappearance of almost all symptoms. At the final evaluation this fact was even more evident (day 21-28). At the study's completion, clinical efficacy (symptoms relief) was considered satisfactory in 100% (40/40) of the cases in the fenticonazole group and 97.5% (39/40) of myconazole group (one way ANOVA [GLM] analysis). The microorganisms more frequently isolated as the causing agents of infection in both groups were Candida albicans, 93% in the fenticonazole group and 85% in the myconazole group. Upon the study's completion, the microbiological efficacy was considered as successful in 97.5% of the cases in both groups (chi square [x2] analysis). The patient's compliance to the treatment was considered satisfactory in 100% in the fenticonazole group and 97.5% in the myconazole group. Tolerance was considered excellent in 100% (40/40) of the fenticonazole cases and in 95% (38/40) of the myconazole cases. Nevertheless, 5% (2/40) of the patients in the myconazole group had minor adverse events that did not require treatment suspension. No adverse events were reported in the fenticonazole group.ConclusionThe results showed that both drugs are equally efficient in treating signs and symptoms of the infection as well as equally effective in the microbiological elimination of the causing agents of the mycotic vulvovaginitis. | Cohen J (1997) [Review of the latest treatments of vulvovaginal mycoses: role of fenticonazole nitrate (Lomexin) in their treatment]. Contraception, fertilite, sexualite (1992) 25, 396-403 [PubMed:9273113] [show Abstract] Candidal vulvovaginitis result from the deficiency of hort defense mechanisms in front of the activity factors of candida. Filamentation and then adhesion of candida to vaginal mucosa is the most important step in the process of infection. The principal virulence factors of candida are its genotypical and phenotypical instability as well as proteinase secretion facilitating adhesion and vaginal mucosa invading. Hort defense mechanisms are essentially constituted by vaginal flora and local cellular immunity. A weakening even moderate of this immunity can favor the spontaneous transformation from asymptomatic colonization to symptomatic vaginitis. The most utilized treatments are imidazol derivates in short courses. The fenticonazole nitrate has the particularity and the recently discovered advantage over the other agents available in single dose regimen to inhihate in vitro the proteinase secretion in a dose dependent manner. The different clinical studies carried out in comparative or non comparative studies have demonstrated its efficiency and tolerance. The most recent studies stress the swiftness of symptoms disappearance. | Balaïsch J (1996) [Evaluation of the time response of a single dose administration of fenticonazole nitrate]. Contraception, fertilite, sexualite (1992) 24, 417-422 [PubMed:8704823] [show Abstract] 174 women with vaginal candidosis confirmed by direct microscopic examination were treated with a single intravaginal fenticonazole nitrate capsule. One third received a second intravaginal capsule three days later. Fenticonazole nitrate cream was also applied daily on the vulvar area in 94.2% of cases. Efficacy was excellent. After one week improvement and complete healing rates were 88% and 80%, respectively. On the second day of treatment pruritus and burning abated in 78% and 85% of women. Mycologic cure demonstrated by microscopic examination was obtained in 92% of cases. Treatment acceptance and tolerance were rated good or excellent by 98% and 92% of patients. Absence of abnormal vaginal discharge due to vaginal capsule was considered as an advantage by women. Results of this trial performed on a large number of patients confirm that product efficacy is fast. | Novelli A, Periti E, Massi GB, Masi R, Mazzei T, Periti P (1991) Systemic absorption of 3H-fenticonazole after vaginal administration of 1 gram in patients. Journal of chemotherapy (Florence, Italy) 3, 23-27 [PubMed:2019858] [show Abstract] Fourteen women, five with normal cervicovaginal mucosa (Group 1), five with cervical carcinoma (Group 2) and four with relapsing vulvovaginal candidiasis (Group 3) were enrolled and completed this open clinical trial. Each subject received a single dose of 1.82 +/- 0.3 g on average of vaginal paste (for ovules) containing about 1000 mg of 3H-fenticonazole nitrate (266 microCi). Twelve hours after vaginal administration, the paste was removed by vaginal washing. Blood, urine and stool samples were collected at specified time intervals for five days. Plasma, urine, stools and all used material in contact with the paste were assayed for radioactivity. No measurable levels of radioactivity were detected in plasma of subjects of Groups 1 and 3 while in 4 of the 5 subjects with cervical carcinoma (Group 2) fenticonazole was detected during the 24 h after administration with a peak level at about 8 hours. For a period of 5 days, 0.4-1.5% of the dose on average was recovered from urine, and 0.18-0.32% from feces. Based on the excretion data, the extent of vaginal absorption of fenticonazole nitrate in women with vulvovaginal candidiasis was 1.81 +/- 0.57% of the dose, while in women with normal cervicovaginal mucosa it accounted for 0.58 +/- 0.28% of the administered dose. In patients with cervical carcinoma, absorption was 1.12 +/- 0.53%. The maximum amount absorbed corresponds to an exposure of about 0.4 mg/kg of fenticonazole nitrate (for a subject weighing 50 kg). Consequently, the vaginal administration of one ovule containing 1000 mg of fenticonazole nitrate seems to be devoid of risk for patients. |
|